Gyon Technologies Capital Management, LP Syndax Pharmaceuticals Inc Transaction History

Gyon Technologies Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$20.64 - $26.24 $727,064 - $924,330	35,226 Added 106.85%	68,195 $1.74 Million
Q3 2022 Nov 14, 2022	SELL	$18.51 - $24.79 $836,892 - $1.12 Million	-45,213 Reduced 57.83%	32,969 $792,000
Q2 2022 Aug 15, 2022	BUY	$13.64 - $19.48 $421,871 - $602,496	30,929 Added 65.45%	78,182 $1.5 Million
Q1 2022 May 12, 2022	SELL	$14.84 - $22.15 $648,226 - $967,534	-43,681 Reduced 48.04%	47,253 $821,000
Q4 2021 Feb 11, 2022	SELL	$15.23 - $22.47 $22,098 - $32,603	-1,451 Reduced 1.57%	90,934 $1.99 Million
Q3 2021 Nov 18, 2021	BUY	$13.87 - $19.8 $1.28 Million - $1.83 Million	92,385 New	92,385 $1.77 Million
Q1 2021 May 17, 2021	SELL	$19.28 - $24.59 $182,735 - $233,064	-9,478 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $143,117 - $250,598	9,478 New	9,478 $211,000

228

88.4M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Gyon Technologies Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Gyon Technologies Capital Management, LP with notifications on news.